---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196974"
form_type: "8-K"
ticker: "BTMD"
cik: "0001819253"
company_name: "biote Corp."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:09:59.782954+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biote Q2 revenue $49.2M, net loss narrows to $10.5M; procedure revenue grows 7.8% sequentially

## Summary
- Revenue of $49.2M; procedure revenue $38.4M, up 7.8% QoQ vs 6.6% in Q1.
- Net loss of $(10.5)M (EPS $(0.19)) improved from $(13.1)M ($(0.25)) in Q2 2023.
- Adjusted EBITDA of $12.7M; gross profit margin 68.9% with $1.2M inventory step-up from Asteria Health acquisition.
- New clinics grew ~30% in H1 2024; 2024 full-year financial guidance reaffirmed.
- BioteRx roll-out on track; management plans further geographic and therapeutic wellness expansion.

## SEC filing metadata
- accession: 0001193125-24-196974
- form_type: 8-K
- ticker: BTMD
- cik: 0001819253
- company_name: biote Corp.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819253/000119312524196974/0001193125-24-196974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819253/000119312524196974/d831251d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196974
- JSON: https://secwatch.observer/filing/0001193125-24-196974.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.